Asston Pharmaceu

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE0SJX01015
  • NSEID:
  • BSEID: 544445
INR
79.00
0.00 (0.00%)
BSENSE

May 12

BSE+NSE Vol: 2000

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 10039662,
    "name": "Asston Pharmaceu",
    "stock_name": "Asston Pharmaceu",
    "full_name": "Asston Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/asston-pharmaceu",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "79.00",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "79.00",
    "mcapval": "68.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 544445,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE0SJX01015",
    "curr_date": "May 12",
    "curr_time": "",
    "bse_nse_vol": 2000,
    "exc_status": "Active",
    "traded_date": "May 12, 2026",
    "traded_date_str": "2026 05 12",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/asston-pharmaceu-10039662-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [],
    "total": 6,
    "sid": "10039662",
    "stock_news_url": "https://www.marketsmojo.com/news/asston-pharmaceuticals-10039662"
  },
  "announcements": [
    {
      "caption": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A",
      "datetime": "30-Apr-2026",
      "details": "<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Asston Pharmaceuticals Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>U24304MH2019PLC324187</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>5.04</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: RISHI UPADHAYA <br/> Designation: COMPANY SECRETARY <br/> EmailId: COMPLIANCE@ASSTONPHARMACEUTICALS.COM</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: SUMIT PAWAR <br/> Designation: CFO <br/> EmailId: SUMITPAWAR98675@GMAIL.COM</div> </div> <div> <br/> Date: 30/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>",
      "source": "BSE"
    },
    {
      "caption": "Shareholder Meeting / Postal Ballot-Outcome of EGM",
      "datetime": "28-Apr-2026",
      "details": "Outcome and Proceedings of the Extraordinary General Meeting held on 28th April 2026 through (VC-OAVM).",
      "source": "BSE"
    },
    {
      "caption": "Shareholder Meeting / Postal Ballot-Scrutinizers Report",
      "datetime": "28-Apr-2026",
      "details": "Voting Result and Scrutinizers Report for EGM held on 28th April 2026 through VC-OAVM",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views
Icon
No Recent News for the Company
stock-recommendationAnnouncement

Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

30-Apr-2026 | Source : BSE

Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1Name of CompanyAsston Pharmaceuticals Ltd
2CIN NO.U24304MH2019PLC324187
3 Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) 5.04
4Highest Credit Rating during the previous FY NA
4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable
5Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the frameworkBSE


We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No



Name of the Company Secretary: RISHI UPADHAYA
Designation: COMPANY SECRETARY
EmailId: COMPLIANCE@ASSTONPHARMACEUTICALS.COM
Name of the Chief Financial Officer: SUMIT PAWAR
Designation: CFO
EmailId: SUMITPAWAR98675@GMAIL.COM

Date: 30/04/2026

Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

Shareholder Meeting / Postal Ballot-Outcome of EGM

28-Apr-2026 | Source : BSE

Outcome and Proceedings of the Extraordinary General Meeting held on 28th April 2026 through (VC-OAVM).

Shareholder Meeting / Postal Ballot-Scrutinizers Report

28-Apr-2026 | Source : BSE

Voting Result and Scrutinizers Report for EGM held on 28th April 2026 through VC-OAVM

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available